key: cord-0981700-mqoqauny authors: Geerts, Hugo; van der Graaf, Piet title: A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID‐19 date: 2020-11-02 journal: Alzheimers Dement (N Y) DOI: 10.1002/trc2.12053 sha: dfa9a15a0cbbf17229137ba8a47a5ee132dd5eac doc_id: 981700 cord_uid: mqoqauny Many ongoing Alzheimer's disease central nervous system clinical trials are being disrupted and halted due to the COVID‐19 pandemic. They are often of a long duration’ are very complex; and involve many stakeholders, not only the scientists and regulators but also the patients and their family members. It is mandatory for us as a community to explore all possibilities to avoid losing all the knowledge we have gained from these ongoing trials. Some of these trials will need to completely restart, but a substantial number can restart after a hiatus with the proper protocol amendments. To salvage the information gathered so far, we need out‐of‐the‐box thinking for addressing these missingness problems and to combine information from the completers with those subjects undergoing complex protocols deviations and amendments after restart in a rational, scientific way. Physiology‐based pharmacokinetic (PBPK) modeling has been a cornerstone of model‐informed drug development with regard to drug exposure at the site of action, taking into account individual patient characteristics. Quantitative systems pharmacology (QSP), based on biology‐informed and mechanistic modeling of the interaction between a drug and neuronal circuits, is an emerging technology to simulate the pharmacodynamic effects of a drug in combination with patient‐specific comedications, genotypes, and disease states on functional clinical scales. We propose to combine these two approaches into the concept of computer modeling‐based virtual twin patients as a possible solution to harmonize the readouts from these complex clinical datasets in a biologically and therapeutically relevant way. the study is being conducted" (FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards March 2020, updated on April 2, 2020). We expect that these events will lead to unprecedented issues of "missingness" in the datasets, probably far beyond the number of missing data usually encountered in clinical trials. At the time of trial pause, there will be patients who have completed the trial, those who started and were at different time points in the trial when it was interrupted, and those who enrolled but have not yet started. We expect a substantial amount of protocol amendments for the patients currently in the trial such as involuntary drug holiday (especially with intravenous [IV] formulations), change in medications (anxiolytics, antidepressants) for addressing mental health issues, and missing site visits that can be partially mitigated by remote monitoring. The involuntary drug holidays are of particular concern as the underlying pathological mechanism that was targeted with the drug is no longer affected and the patient faces a completely new pathological environment when the drug trial is restarted. In addition, because each patient starts at a unique time, they are at different points in their pathological trajectory at the time of interruption. In addition, there will be subjects from the last two groups that will not return to the trial once it restarts because AD patients face an additional burden due to their age, fragility, comorbidity, comedication, and other factors. The number of patients that have completed the trial is likely to be insufficient to achieve the power for detecting a clinically relevant improvement. In the worst-case scenario the whole trial needs to start over again, delaying any possible successful treatment for a number of years and at an enormous cost for sponsors, patients, and their caregivers. We cannot afford to lose all the information collected so far from these interrupted trials; therefore, we must explore all possible avenues to recover as much knowledge as possible. Traditional statistical methods such as last observation carried forward for accounting for missing data will be a first step to address this issue. However, because many of the disease-modifying studies follow the patients over 1 to 2 years, the number of missing subjects with protocol amendments can be considerable. For example, consider a regular 18-month phase III study enrolling about 600 patients/year (50/month) with an anticipated enrollment of 1800 patients. In this case when the trials are halted at any point between 18 and 32 months after start of enrollment, up to 60% of subjects in the trial can face substantial disruptions. One novel analytical method to address this "missingness" is a virtual twin patient approach, based on mechanistic modeling, including physiologically based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP). PBPK modeling uses virtual populations to predict drug performance across all human organs, based on in vitro and in vivo data. PBPK can predict drug exposure levels in the tissue of interest (here the brain) based on patient, drug characteristics, concomitant medications, and genotypes of metabolizing enzymes and is encouraged by regulators. QSP then builds on PBPK by integrat-ing quantitative drug data with knowledge of its mechanism of action. For complex, heterogeneous diseases such as AD, QSP predicts how drugs modify key cellular and neuronal networks involved in cognition in space and time and how functional readouts are impacted by human pathophysiology and the drug's pharmacology. To model the pharmacodynamic and efficacy effects, a virtual twin QSP model of trial subjects, using the same comedications, genotypes, biomarkers, amyloid beta (Aβ) and tau load as in the real trial can be created. Because the pharmacology and target exposure of central nervous system (CNS) active comedications in current AD clinical practice is well documented, and the pharmacodynamical effect of certain common genotype variants can be derived from imaging studies, 9, 25 we can create virtual twin patients with the same characteristics. Modeling the pharmacology and the pharmacokinetic profile of the investigative drug together will allow researchers to simulate the cognitive trajectory of these individual virtual patients. Introducing information from imaging and biofluid biomarkers could further help define both levels of target engagement for the investigative drug and disease state. This mechanism-based QSP approach has been successfully applied in blindly predicting an unexpected clinical phase I scopolamine challenge study in healthy volunteers with a drug affecting a new yetuntested target (Nicholas et al. 20 ). The modeling platform also was able to generate a testable hypothesis on the cognitive worsening of β-site amyloid precursor protein cleaving enzyme (BACE) inhibitors 13 and the different outcomes for the two phase III trials with aducanumab in AD. 12 In a different indication and with regard to pharmacodynamical drug-drug interactions, the model has documented the interaction between acetylcholinesterase inhibitors, memantine, smoking, and antipsychotics on cognitive outcome in a schizophrenia population. 11 In this particular case, the model was able to reconcile discordant findings in the literature. Parkinson's Disease Rating Scale (UPDRS)-calibrated QSP model for motor symptoms in Parkinson's disease. 22 This model blindly predicted the complex pharmacodynamical interactions on extrapyramidal motor symptoms in a real-world clinical practice dataset of schizophrenia patients while on two antipsychotics. 16 Pharmacokinetic central profile of active compound in the human brain A computer simulation model of each patient focusing on drug levels, replicates the patient's various individual attributes that affect a drug's fate in their body and hence its effects. These attributes include the patient's age, weight, height, sex, ethnicity, and genetics of drug metabolizing enzymes and drug transporters. The simulation outcome takes into account the patient's current drug dosage, fed or fasted state, comorbid conditions and comedications that affect the activity of certain metabolic enzymes and transporters, and level of organ function. As an example this platform was used to accurately predict olanzapine exposure in individual patients for model-informed precision dosing. 21 Another computer model 10 simulates the interaction of pharmacological agents with transporters at the blood-brain barrier (BBB) to derive an estimate of brain or cerebrospinal fluid (CSF) penetration. This model can be adapted to the BBB in demented patients using the documented protein composition and distribution. 1 In addition, PBPK models have been developed for the uptake of monoclonal antibodies. 3 Taken together, integration of these models can inform the central drug levels at an individual patient basis. The calibrated QSP model for cognition in AD has been extensively described before (Roberts et al. 23 The receptor model has been described in detail in other works 27, 28 (see section S1 in supporting information). Basically, this module simulates the competition between neurotransmitters, active moiety of drugs, and positron emission tomography (PET) tracer molecules (if present) at the postsynaptic receptor, for example a dopamine synapse under natural in vivo firing conditions. The model can be extended to other neurotransmitter systems such as serotonin, norepinephrine, and cholinergic systems and can also be used to determine the impact of common gene variants on neurotransmitter dynamics (see below). Target engagement of donepezil, an AChE-inhibitor with a K i of 20 nM 30 is derived from imaging studies with 11 C-PMP. 11 This corresponds to brain AChE-inhibition levels of 35% at 10 mg 6,24 and leads to ACh half-lives of 6.9 and 7.7 milliseconds for donepezil at 5 and 10 mg and to half-lives of 5.9, 6.8, and 7.7 milliseconds for galantamine at 8, 16, and 24 mg with similar outcomes for rivastigmine. The subsequent changes in ACh half-life affects activation levels of muscarinic and nicotinic receptors, leading to corresponding modifications in glutamate and GABA (see Table S2 in supporting information for biological references). In addition, the small allosteric potentiating effect of galantamine on nAChR 30 is implemented as a 10% or 15% (respectively, for 16 and 24 mg) relative increase in both α 7 nAChR and α 4 β 2 nAChR activation levels. Memantine is a relatively weak NMDA-R inhibitor that has a larger affinity for the NMDA-NR2C/2D subunit 18 in physiological conditions. Based upon the observation that the NR2C/2D subunits are preferentially located on inhibitory interneurons, 19 memantine's pharmacology is implemented using a two-fold greater inhibition on interneurons as compared to pyramidal cells. Data further suggest that the functional memantine concentration in the human brain is relatively small in the range of a 1% decrease in gNMDA on interneurons. 23 First-generation benzodiazepines (such as lorazepam) are implemented as agonists at the GABA-A α1 and GABA-A α2 receptor. The α1 receptor is localized both on inhibitory-excitatory and on inhibitory-inhibitory GABAergic synapses, while α2 is predominantly located at the inhibitory-excitatory synapses. Second-generation benzodiazepines such as midazolam more preferentially affecting the α2R, are implemented by reducing the effect at the α1 inhibitory-inhibitory synapses by 50% compared to the effect at α2 inhibitory-excitatory synapses. Different doses can be implemented ranging from 2.5% to 10% reduction at α1R. Anti-depressants are implemented by increasing the half-life of serotonin dose-dependently between 6.25% and 25% increase with corresponding effects on all the 5-HTR implemented in the model using the receptor competition model, described above with published 11 C-raclopride displacements. The same receptor competition model can be used to determine the pharmacodynamic effect of genotypes. To reproduce experimental findings that the COMTVal158Met genotype affects the displacement of the D 1 R PET radiotracer NNC-112 in healthy unmedicated volunteers, 25 Apolipoprotein E (APOE) genotypes can be implemented using different synapse densities with APOE4 homozygotes a 20% lower and non-APOE4 carriers had a 20% higher synapse density compared to APOE4 heterozygote genotype. 4,8,17 The effect of amyloid load on cognitive outcome has been described in detail in other works. 12, 13 Basically, the differential dose-dependent effect of short (Aβ40) and long (Aβ42) forms on glutamatergic 29 The effect of tau pathology on neuronal firing dynamics and brain region activity can be simulated based on preclinical data illustrating the effect of tau oligomers on action potential characteristics, most notably the widening of the action potential profile. 14 This can be basically reproduced by reducing Na-conductance at the axon initial segment (AIS) and K+ conductance in other compartments of the neuronal cells. This is in line with electrophysiology measurements in an FTD V337M hIPSC cell line. 26 Widening the action potential can affect neuronal synchronization and affect emerging properties in networks that are related to cognitive outcome. For tau modulating agents affecting spatio-temporal progression of tau pathology, an extensive QSP model has been developed that includes tau secretion, extracellular processes such as capture by antibodies, diffusion along the axonal sheet, and binding to acceptor molecules; internalization, axonal transport along microtubule, oligomerization with endogenous tau, and degradation of misfolded tau protein to secretion into the next synapse. 7 This model has been extensively validated with preclinical and clinical data. A particularly interesting aspect of this approach is the de-risking of the model's predictability by introducing a number of validation steps. This can take place in three steps (see Figure 1 ). It might be possible to derive relationships between these scales, as they are all functional. An alternative possibility is to normalize all readouts back to the ADAS-Cog outcome, generated by the predictive platform, and compare that outcome between the treatment arms. Finally, another major limitation of this approach is the unknown central effects of the SARS CoV-2 virus for those patients who become infected; these might interfere with the AD pathology or at least impact the functional cognitive readout. Importantly, the validation steps (especially step 3) outlined above can address this possibility in more detail. In summary, a virtual twin approach using QSP with the extensive validation as outlined in this paper, can enable the extrapolation of the clinical trajectory for the many patients unable to complete the trial, thereby helping to salvage the information gathered at substantial human and investment cost for the research participants, their family members, health-care professionals, and sponsors. When the trial restarts (likely with a new protocol), the platform in principle can bridge the before and after to hopefully salvage the investment and communicate continuity of information with scientists and regulators. The authors are employees of Certara-SimCyp. Proteomic quantification of human blood-brain barrier slc and abc transporters in healthy individuals and dementia patients Automated design of ligands to polypharmacological profiles A translational platform PBPK model for antibody disposition in the brain Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine A computer model simulating the effect of Tau antibodies on the inter-cellular spread of Tau ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo 5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [(11)C]SB207145 PET in humans Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: estimating time varying CSF drug concentrations and their variability using in vitro data Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model Introduction of tau oligomers into cortical neurons alters action potential dynamics and disrupts synaptic transmission and plasticity Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine Developmental and regional expression in the rat brain and functional properties of four NMDA receptors Systems Pharmacology Modeling in Neuroscience: Prediction and Outcome of PF-04995274, a 5HT4 Partial Agonist, in a Clinical Scopolamine Impairment Trial. Advances Alzheimer's Dis Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease A) Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development Multiple effects of beta-amyloid on single excitatory synaptic connections in the PFC Nicotinic cholinergic modulation: galantamine as a prototype How to cite this article: Geerts H, van der Graaf P. A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID-19